<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971058</url>
  </required_header>
  <id_info>
    <org_study_id>IXIARO-booster senescence</org_study_id>
    <secondary_id>2016-002894-36</secondary_id>
    <nct_id>NCT03971058</nct_id>
  </id_info>
  <brief_title>Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.</brief_title>
  <official_title>Characterisation of Cellular and Humoral Immune Responses Following the First Booster Immunisation With the Inactivated, Purified Japanese Encephalitis Vaccine IXIARO® in Elderly Compared to Young Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the immune responses following a booster immunisation
      with the Japanese Encephalitis vaccine in elderly subjects (above 60 years of age) in
      comparison to a young study group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The condition under investigation is the naturally aging immune system. The aim of this study
      is to investigate the immune responses following a booster immunisation with the Japanese
      Encephalitis vaccine in elderly subjects (above 60 years of age) in comparison to a young
      study group.Testing the difference of the JEV-antibody titre increase between young and
      elderly adults between visit 1 (before booster vaccination) and up to visit 4 (6 months after
      booster vaccination).

      Testing cellular immunity (cytokine production after JEV as well as TBE stimulation) on visit
      1, 2 (one week after booster immunisation) and 3 between both age groups.

      Testing of surface markers of different T and B cell subsets before and after JE-booster
      vaccination (on visit 1-3) in comparison between both age groups.

      Testing TBE-antibody titres before and after JE-booster vaccination (on visit 1-4) in both
      age groups.

      Testing CMV serology at visit 1 in both age groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>JEV antibody titer increase/course between visit 1 (before the booster vaccination) and Visit 3</measure>
    <time_frame>Visit 3 day 42+/-4</time_frame>
    <description>Testing the difference of the JEV antibodies increase between young and elderly adults between Visit 1 (before booster vaccination) and Visit 3 (day 42+/-4 after Booster vaccination)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing the difference of the JEV antibody titer between young and elderly adults</measure>
    <time_frame>Visit 1, day 0) till Visit 4 (day 168 +/- 14)</time_frame>
    <description>Testing the difference of the JEV antibody titer before the booster vaccination with IXIARO® (Visite 1, day 0) till Visit 4 (day 168 +/- 14) in comparison between the age groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testing cellular immunity</measure>
    <time_frame>Visit 1, day 0), seven days after booster vaccination (Visit 2, day 7 (+2).</time_frame>
    <description>Testing cellular immunity (cytokine production of IL-2, IFN-g, TNF-alpha, IL-6, IL-10, IL-21 after stimulation with JEV antigen) before the booster vaccination with IXIARO® (Visit 1, day 0), seven days (Visit 2, day 7 (+2) after and after 42 days (Visit 3, day 42 (+/-4)) after that in comparison between the age groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testing of lymphocyte populations with FACS analysis</measure>
    <time_frame>Visit 1, day 0), seven days after booster vaccination (Visit 2, day 7 (+2) and 42 days (Visit 3, day 42 (+/-4) after booster vaccination</time_frame>
    <description>Testing of lymphocyte populations via testing surface markers of different B and T cell subsets with FACS and bloodcount</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testing of CMV serology</measure>
    <time_frame>Visit 1, day 0</time_frame>
    <description>Testing of CMV Seropositivity at the time of the booster vaccination with IXIARO® at Visit 1 (day 0) in both age groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBE titer increase/course</measure>
    <time_frame>Visit 1, day 0), seven days (Visit 2, day 7 (+2), 42 days (Visit 3, day 42 (+/-4) und 6 Months (Visit 4, day 168 (+/- 14)</time_frame>
    <description>Tick borne encephalitis titer before booster vaccination with IXIARO® (Visit 1, day 0), seven days after the booster vaccination (Visit 2, day 7 (+2),and 42 days (Visit 3, day 42 (+/-4) after the booster vaccination and 6 months (Visit 4, day 168 (+/- 14) after the booster vaccination and the in comparison between age groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testing of cellular immunity-Testing of cytokine production</measure>
    <time_frame>Visit 1, day 0; Visit 2, day 7 (+2)</time_frame>
    <description>Testing of cellular immunity (cytokine production of IL-2, TNF-alpha, IL-6, IL-10 after stimulation mit TBE Antigen) before and seven days after the booster vaccination with IXIARO® (Visit 1, day 0; Visit 2, day 7 (+2) in comparison between the age groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Japanese Encephalitis Vaccine</condition>
  <arm_group>
    <arm_group_label>young individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elderly individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immune Responses After a Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IXIARO®- Japanese Encephalitis vaccine</intervention_name>
    <description>Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine</description>
    <arm_group_label>elderly individuals</arm_group_label>
    <arm_group_label>young individuals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participation in the preceeding study &quot;IXIARO®-senescence&quot; (EudraCTno: 2010-018630-52)
             without protocoll violation OR 2 documented IXIARO® vaccinations 28 days (-8/+ 30
             days) apart between January 2010 and April 2014 at the age of 18 to 40 years or above
             the age of 60.

          -  good state of health including individuals with medically controlled minor underlying
             disease (such as hypertension, hypercholesterinemia, NIDDM)

          -  willingness to sign written informed consent

        major Exclusion Criteria:

          -  Already received an booster (3rd dose) of IXIARO ®

          -  Vaccination with other JE vaccine (e.g. Je-vax)

          -  clinically manifest infection with another Flavivirus within 1 year prior study
             inclusion (yellow fever, Dengue fever, West Nile, TBE)

          -  past infection with the JEV

          -  vaccination against yellow fever, Dengue, West Nile within 6 months prior to study
             inclusion

          -  TBE vaccination within the last 30 days prior to study inclusion

          -  immunosuppressive therapy (intake&gt;14d) within 30 days before IXIARO booster till V3
             (day 42+/-4), Corticosteroids like Prednisolon &gt; and = 20mg/day; allowed: topic or
             inhalative application

          -  immunodeficiency or st. p. organ transplantation

          -  autoimmune disease except vitiligo or diseases of the thyroid gland with thyroid
             hormon substitution therapy

          -  immuntherapy within 2 weeks before or after Ixiaro Booster

          -  current acute infection or exacerbation of a chronic illness

          -  cancer within the last 5 years

          -  clinically significant haematological, renal, pulmonary, hepatic, neurological,
             cardiovascular disease which is not treated adequately within 12 weeks before Ixiaro
             booster

          -  known infection with HIV, Hep B and Hep C

          -  Guillain - Barré- Syndrome (GBS) - anamnestic

          -  anamnestic anaphylaxie, atopy oder severe hypersensivity against ingredients of IXIARO

          -  drug abuse/alcohol abuse

          -  pregnancy and breastfeeding

          -  plasma donation within the last 4 months

          -  receiving blood or immunglobulins within 3 months before v1

          -  significant mental disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ursula Wiedermann-Schmidt, Univ Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, ISPTM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Studien Team</last_name>
    <phone>+43140160</phone>
    <phone_ext>38276</phone_ext>
    <email>isptm-studien@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ines Zwazl, BA</last_name>
    <phone>+43140160</phone>
    <phone_ext>38276</phone_ext>
    <email>ines.zwazl@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Studien Team</last_name>
      <phone>+43140160</phone>
      <phone_ext>38276</phone_ext>
      <email>isptm-studien@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Ines Zwazl, BA</last_name>
      <phone>+43140160</phone>
      <phone_ext>38202</phone_ext>
      <email>ines.zwazl@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Institute of Specific Prophylaxis and Tropical Medicine</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Wiedermann, MD, PhD</last_name>
      <phone>0043 1 40160</phone>
      <phone_ext>38260</phone_ext>
      <email>ursula.wiedermann@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ursula Wiedermann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Univ. Prof. Dr. Ursula Wiedermann</investigator_full_name>
    <investigator_title>Univ.-Prof. MD PhD</investigator_title>
  </responsible_party>
  <keyword>Japanese Encephalitis vaccine</keyword>
  <keyword>immune responses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

